Check-Cap (CHEK) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CHEK shares.
View CHEK analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price objectives for Check-Cap's stock. Their CHEK share price forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 283.6% from the stock's current price.
View analysts price targets for CHEK or view top-rated stocks among Wall Street analysts.

Check-Cap's stock was trading at $2.20 at the beginning of the year. Since then, CHEK stock has decreased by 17.1% and is now trading at $1.8248.
View the best growth stocks for 2023 here.

Check-Cap saw a increase in short interest in May. As of May 15th, there was short interest totaling 50,900 shares, an increase of 226.3% from the April 30th total of 15,600 shares. Based on an average daily trading volume, of 63,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the company's stock are sold short.
View Check-Cap's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023.
View our CHEK earnings forecast.

Check-Cap Ltd. (NASDAQ:CHEK) released its quarterly earnings results on Friday, March, 31st. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.04.

Check-Cap shares reverse split before market open on Friday, November 25th 2022. The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Check-Cap investors own include Alibaba Group (BABA), Navios Maritime Partners (NMM), New Residential Investment (NRZ), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Acasti Pharma (ACST), Avinger (AVGR), Biocept (BIOC) and Purple Biotech (KTOV).

(CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager.

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

Check-Cap's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sabby Management LLC (1.31%) and Susquehanna International Group LLP (0.83%).

Shares of CHEK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHEK stock can currently be purchased for approximately $1.82.

Check-Cap (NASDAQ:CHEK) has a market capitalization of $8.80 million. The medical research company earns $-19,110,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The official website for the company is www.check-cap.com. The medical research company can be reached via phone at 972546706451, via email at jeremy@lifesciadvisors.com, or via fax at 972-4821-1267.